Mu Junjie, Li Ying, Chen Qiuxiong, Xiao Yujie, Hu Min, He Ziyue, Zeng Jun, Ding Yiling, Song Pengyang, He Xiao, Yang Xian, Zhang Xue
Engineering Research Center for Biotechnology of Active Substances, Ministry of Education/Chongqing Normal University, Chongqing, 401331, PR China.
Pengshui County Forestry Bureau, Chongqing, 409600, PR China.
J Ethnopharmacol. 2025 Jan 30;337(Pt 3):118918. doi: 10.1016/j.jep.2024.118918. Epub 2024 Oct 11.
In Traditional Chinese Medicine (TCM), there are many prescriptions for treating breast cancer (BC) that utilize the herb Epimedium brevicornum Maxim, which warms and replenishes kidney yang. Baohuoside I (BI) is a flavonoid compound found in Epimedium brevicornum Maxim. As a single glycoside, it is not easily hydrolyzed in the intestine and is typically absorbed as a precursor. As a natural product with potential anti-cancer properties, studies have shown that BI possesses anti-cancer activity and can inhibit the invasion and migration of BC cells. However, its underlying mechanisms remain unclear, thus further research is needed to validate its modern mechanisms for traditional uses.
This study aimed to explore the regulatory mechanism of BI in the signaling pathways of BC cells through network pharmacology (NP), molecular docking (MD) techniques and cellular experiments.
Potential targets were predicted using public databases, and a protein-protein interaction (PPI) network was constructed. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses were performed. Key signaling pathways were validated through MD techniques, cellular experiments, RNA interference and Western blot (WB) analysis.
Treatment-associated targets included SRC, MAPK1, HSP90AA1, PIK3CA, TP53, AKT1, and EGFR. GO enrichment, KEGG enrichment analyses, and MD results indicated that BI exerts its anti-breast cancer effects by inhibiting the tyrosine kinase activity of EGFR, as well as through downstream MAPK signaling pathway and PI3K-Akt signaling pathway pathways. In vitro experiments confirmed that BI primarily induce cell apoptosis through the EGFR-mediated MAPK signaling pathway and PI3K-Akt signaling pathway.
BI can inhibit EGFR activation and promote BC cell apoptosis through the MAPK signaling pathway and PI3K-Akt signaling pathway, thereby exerting therapeutic effects on BC. This study not only provides experimental evidence for the accuracy of NP but also offers an effective approach for rational utilization of Baohuoside I-like flavonoid compounds as anti-breast cancer drugs.
在传统中医(TCM)中,有许多治疗乳腺癌(BC)的方剂使用淫羊藿,其具有温补肾阳的功效。宝藿苷I(BI)是淫羊藿中发现的一种黄酮类化合物。作为单一糖苷,它在肠道中不易水解,通常以前体形式被吸收。作为一种具有潜在抗癌特性的天然产物,研究表明BI具有抗癌活性,可抑制BC细胞的侵袭和迁移。然而,其潜在机制尚不清楚,因此需要进一步研究以验证其传统用途的现代机制。
本研究旨在通过网络药理学(NP)、分子对接(MD)技术和细胞实验探索BI在BC细胞信号通路中的调控机制。
利用公共数据库预测潜在靶点,并构建蛋白质-蛋白质相互作用(PPI)网络。进行基因本体(GO)和京都基因与基因组百科全书(KEGG)富集分析。通过MD技术、细胞实验、RNA干扰和蛋白质免疫印迹(WB)分析验证关键信号通路。
与治疗相关的靶点包括SRC、MAPK1、HSP90AA1、PIK3CA、TP53、AKT1和EGFR。GO富集、KEGG富集分析和MD结果表明,BI通过抑制EGFR的酪氨酸激酶活性以及下游MAPK信号通路和PI3K-Akt信号通路发挥抗乳腺癌作用。体外实验证实,BI主要通过EGFR介导的MAPK信号通路和PI3K-Akt信号通路诱导细胞凋亡。
BI可通过MAPK信号通路和PI3K-Akt信号通路抑制EGFR激活并促进BC细胞凋亡,从而对BC发挥治疗作用。本研究不仅为NP的准确性提供了实验证据,还为合理利用宝藿苷I类黄酮化合物作为抗乳腺癌药物提供了有效途径。